

[Des-His1,Glu9] Glucagon

Cat. No.:	HY-P3608
CAS No.:	110121-11-4
Molecular Formula:	C ₁₄₈ H ₂₂₀ N ₄₀ O ₄₈ S
Molecular Weight:	3359.63
Sequence Shortening:	SQGTFTSEYSKYLDSRRAQDFVQWLMNT
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes [1].								
IC₅₀ & Target	Glucagon Receptor ^[1]								
In Vitro	[Des-His1,Glu9] Glucagon (1 pM-100 μM) does not activate membrane-bound adenylate cyclase up to a concentration of 2×10 ⁻⁴ molar in the cAMP assay on isolated rat liver membranes (from male Sprague Dawley rats) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	[Des-His1,Glu9] Glucagon (3.6-4.0 μg/kg for rabbits, 1 mg/kg for rats; i.v.; single dosage) suppresses hyperglycemic effects in rabbits and rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table> <tr> <td>Animal Model:</td> <td>New Zealand rabbits (2.8-3.8 kg; fasted for 18 hours)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3.6-4.0 μg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.; single dosage</td> </tr> <tr> <td>Result:</td> <td>Suppressed hyperglycemic response of glucagon.</td> </tr> </table>	Animal Model:	New Zealand rabbits (2.8-3.8 kg; fasted for 18 hours) ^[1]	Dosage:	3.6-4.0 μg/kg	Administration:	i.v.; single dosage	Result:	Suppressed hyperglycemic response of glucagon.
Animal Model:	New Zealand rabbits (2.8-3.8 kg; fasted for 18 hours) ^[1]								
Dosage:	3.6-4.0 μg/kg								
Administration:	i.v.; single dosage								
Result:	Suppressed hyperglycemic response of glucagon.								
	<table> <tr> <td>Animal Model:</td> <td>Male Wistar rats weighing [350-400 mg; hyperglycemia induced by i.p. injection of 65 mg/kg Streptozotocin (HY-13753)]^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenously administration through the tail vein; single dosage</td> </tr> <tr> <td>Result:</td> <td>Decreased blood glucose rapidly, and reduced hyperglycemic effect by 70% within 5 min.</td> </tr> </table>	Animal Model:	Male Wistar rats weighing [350-400 mg; hyperglycemia induced by i.p. injection of 65 mg/kg Streptozotocin (HY-13753)] ^[1]	Dosage:	1 mg/kg	Administration:	Intravenously administration through the tail vein; single dosage	Result:	Decreased blood glucose rapidly, and reduced hyperglycemic effect by 70% within 5 min.
Animal Model:	Male Wistar rats weighing [350-400 mg; hyperglycemia induced by i.p. injection of 65 mg/kg Streptozotocin (HY-13753)] ^[1]								
Dosage:	1 mg/kg								
Administration:	Intravenously administration through the tail vein; single dosage								
Result:	Decreased blood glucose rapidly, and reduced hyperglycemic effect by 70% within 5 min.								

REFERENCES

[1]. Unson CG, et al. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides. 1989 Nov-Dec;10(6):1171-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA